Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | DAO | P14920 | 2/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL106114 | 0.87 | NPC1 (0.43) | NPC1RAB9ADAOFFAR1MTNR1A | |
| SCHEMBL3601000 | 0.84 | FFAR1 (0.57) | NPC1RAB9AFFAR1POLBSMN1; SMN2 | |
| SCHEMBL9012908 | 0.83 | L3MBTL1 (0.43) | POLBTDP1MAOB | |
| SCHEMBL2438835 | 0.83 | NPC1 (0.50) | NPC1RAB9AAPPPOLBSMN1; SMN2 | |
| SCHEMBL104633 | 0.83 | MTNR1A (0.42) | NPC1RAB9ADAOFFAR1MTNR1A | |
| Hydrochloric Acid SCHEMBL10894906 | 0.82 | L3MBTL1 (0.42) | POLBTDP1MAOB | |
| SCHEMBL9366663 | 0.79 | NPC1 (0.48) | NPC1RAB9AAPPPOLBSMN1; SMN2 | |
| SCHEMBL9741507 | 0.78 | RAB9A (0.51) | NPC1RAB9AFFAR1MTNR1AMTNR1B | |
| SCHEMBL2433142 | 0.76 | NPC1 (0.48) | NPC1RAB9ADAOFFAR1APP | |
| SCHEMBL3600996 | 0.74 | POLB (0.44) | NPC1RAB9AFFAR1MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202399-B2 | Dihydroxy aromatic heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-02-12 | — | — | US | disclosed |
| US-20170107226-A1 | DIHYDROXY AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2017-04-20 | — | — | US | disclosed |
| US-9562020-B2 | Dihydroxy aromatic heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-07 | — | — | US | disclosed |
| US-20160039771-A1 | DIHYDROXY AROMATIC HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-02-11 | — | — | US | disclosed |
| US-9212147-B2 | Dihydroxy aromatic heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-15 | — | — | US | disclosed |
| US-20140336165-A1 | DIHYDROXY AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039771-A1 | DIHYDROXY AROMATIC HETEROCYCLIC COMPOUND | DAO, DDO, DDC | NPC1 4166/4885RAB9A 1453/4885DAO 1/4885 |
| US-10202399-B2 | Dihydroxy aromatic heterocyclic compound | DAO, DDO, DDC | NPC1 4160/4885RAB9A 1420/4885DAO 1/4885 |
| US-20140336165-A1 | DIHYDROXY AROMATIC HETEROCYCLIC COMPOUND | DAO, DDO, DDC | NPC1 4160/4885RAB9A 1420/4885DAO 1/4885 |
| US-20170107226-A1 | DIHYDROXY AROMATIC HETEROCYCLIC COMPOUND | DAO, DDO, DDC | NPC1 4160/4885RAB9A 1420/4885DAO 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.